• 2025考研復(fù)試伴學(xué)班
• 2025考研復(fù)試標(biāo)準(zhǔn)班
• 2026考研英語全程班
• 26考研全科上岸規(guī)劃營「擇校▪規(guī)劃▪備考」
• 中國藥科大學(xué)2025考研專業(yè)課復(fù)習(xí)資料「真題▪筆記▪講義▪題庫」

宗莉，藥劑學(xué)專業(yè)教授，博士生導(dǎo)師，藥學(xué)博士。專業(yè)研究方向：緩控釋制劑和生物技術(shù)藥物遞送系統(tǒng)。在緩控釋制劑領(lǐng)域，有二十多年研究經(jīng)歷，研究興趣：擇時控釋制劑、難溶藥物緩釋制劑。自2002年涉足生物技術(shù)藥物遞送系統(tǒng)，獲此領(lǐng)域2004年、2006年和2010年度國家自然科學(xué)基金，研究興趣：基因遞藥系統(tǒng)、粘膜免疫、多肽/蛋白質(zhì)非注射給藥。

科研成果：主持完成國家自然科學(xué)基金項(xiàng)目3項(xiàng)、寧夏科委攻關(guān)項(xiàng)目1項(xiàng)和江蘇省高新技術(shù)創(chuàng)業(yè)中心項(xiàng)目1項(xiàng)。參與完成十一五國家“重大新藥創(chuàng)制”科技重大專項(xiàng)、“863”項(xiàng)目、“八五”國家重點(diǎn)科技攻關(guān)項(xiàng)目和江蘇省自然科學(xué)基金項(xiàng)目。

近年以項(xiàng)目負(fù)責(zé)人獲新藥證書3本、一類新藥臨床批文1份。協(xié)助企業(yè)完成多項(xiàng)新藥的產(chǎn)業(yè)化轉(zhuǎn)化，獲藥品注冊批件4份。另外以分課題負(fù)責(zé)人參與完成新藥產(chǎn)品3項(xiàng)。以第一發(fā)明人獲新制劑和新工藝授權(quán)專利6項(xiàng)，其中3項(xiàng)專利權(quán)轉(zhuǎn)讓或?qū)＠麑?shí)施許可。

承擔(dān)本科生課程《藥劑學(xué)》、碩士生課程《生物藥劑學(xué)》和《現(xiàn)代藥劑學(xué)選論》教學(xué)工作，在國際和國內(nèi)核心期刊發(fā)表研究論文40余篇，獲2008和2009年度江蘇省優(yōu)秀碩士學(xué)位論文2篇，獲2011年江蘇省研究生科研創(chuàng)新計劃項(xiàng)目等。

近5年發(fā)表的主要文章：

[1]Xiying Yuan, Xiaorong Yang, Danning Cai, Dan Mao, Jie Wu, Li Zong* et al. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2008, 26: 3727-3734

[2]Xiaorong Yang, Xiying Yuan, Danning Cai, Shaoying Wang, Li Zong* Low molecular weight chitosan in DNA vaccine delivery via mucosa. Int J Pharm, 2009, 375: 123-132

[3]Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, Cao R, Roque RS, Zong L, Liu J, Li T. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.Clin Vaccine Immunol, 2009, 16: 1033-1039

[4]Hou Jing, Lu Yong, Liu Haiyan, Zong Li*, Liu Jingjing, Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 2011, 29: 4102-4109

[5]Wenjun Yao, Yan Jiao, Juan Luo, Mingzhu Du, Li Zong*, Practical synthesis and characterization of mannose-modified chitosan. Int J Biol Macromol, 2012, 50: 821-825

[6]Ling Wang, Fan Zeng, Li Zong*, Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex. Pharm Dev Technol, 2013, 18: 1101-1110

[7]Zeng F, Wang L, Zhang W, Shi K, Zong L*. Formulation and In Vivo Evaluation of Orally Disintegrating Tablets of Clozapine/Hydroxypropyl-β-cyclodextrin Inclusion Complexes. AAPS PharmSciTech, 2013, 14: 854-860

[8]Yao Wenjun, Peng Yixing, Du Mingzhu, Luo Juan, Zong Li*. Preventative vaccine loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm, 2013, 10: 2904-2914

[9]Su Z, Shi Y, Xiao Y, Sun M, Ping Q*, Zong L*, et al. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization. Int J Pharm, 2013, 447: 281-192

[10]Ling Wang, Yanyu Xiao, Minglei Chen, Fan Zeng, Li Zong*, Pharmacokinetics of orally disintegrating tablets of perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex in rabbits. Pharmazie, 2013, 68: 1-5

聯(lián)系方式：Tel:025－83271317；13951603932

E-mail:zongcpu@hotmail.com